Revance Therapeutics
RVNC
HK$28.41
Share price
0.00%
Change (1 day)
-19.54%
Change (1 year)
Categories
Operating Margin for Revance Therapeutics (RVNC)
Operating Margin as of April 2025 (TTM): -63.25%
According to Revance Therapeutics's latest financial reports and stock price the company's current Operating Margin is -63.25%. At the end of 2023 the company had an Operating Margin of -130.03%.
Operating Margin history for Revance Therapeutics from 2013 to 2024
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2023 | -130.03% | -49.19% |
| 2022 | -255.91% | -27.61% |
| 2021 | -353.53% | -79.9% |
| 2020 | -1,758.96% | -95.44% |
| 2019 | -38,602.66% | 931.72% |
| 2018 | -3,741.59% | -91.84% |
| 2017 | -45,851.15% | 55.98% |
| 2016 | -29,396.00% | 22% |
| 2015 | -24,095.33% | 76.64% |
| 2014 | -13,640.99% | 125.74% |
| 2013 | -6,042.79% | 47.87% |
| 2012 | -4,086.47% | -15.92% |
| 2011 | -4,860.50% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 | -856.84% | 1,254.69% | 🇺🇸 USA |
 | 18.78% | -129.69% | 🇺🇸 USA |
 | 19.69% | -131.13% | 🇺🇸 USA |
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.